x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0231232
| Product Information | |
|---|---|
| CAS No. | 857531-00-1 |
| Chemical Name | 4-(4-chlorophenyl)-4-[4-(1H-pyrazol-4-yl)phenyl]piperidine |
| Formula | C20H20ClN3 |
| Molecular Weight | 337.85 |
| PubChem CID | 11175137 |
| SMILES | C1CNCCC1(C2=CC=C(C=C2)C3=CNN=C3)C4=CC=C(C=C4)Cl |
| Target | PKB / AKT |
| Product Description | AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM in cell-free assays, respectively little activity outside the AGC kinase family. |
| Format & Storage | |
|---|---|
| Purity | > 98% |
| Source | Synthetic |
| Shipping | Shipped on dry ice. |
| Storage | Store at -20 °C. |
| Solubility Overview | ≥16.9mg/mL in DMSO, ≥4.38 mg/mL in EtOH with ultrasonic, ≥45 mg/mL in H2O |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
